NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced a collaboration with Mayo Clinic to support a newly funded research program evaluating a novel treatment approach for pediatric diffuse midline glioma (DMG), one of the most aggressive and difficult-to-treat childhood brain cancers. The program is supported by a grant from the Children's Cancer Research Fund (CCRF) awarded to Mayo Clinic investigators Dr. David Daniels and Dr. Liang Zhang.
The research project seeks to address a fundamental challenge in treating malignant brain tumors: achieving and maintaining therapeutic drug concentrations within the tumor. While convection-enhanced delivery (CED) enables drugs to bypass the blood-brain barrier through direct intracranial infusion, therapeutic benefit may be limited by rapid clearance of drugs from the treatment site. The Mayo Clinic team will evaluate a novel combination therapy strategy designed to enhance intratumoral drug retention by modulating drug efflux mechanisms, with the goal of prolonging therapeutic exposure following localized drug delivery. The project will begin with large animal studies and may expand to human studies in the future.
The study will utilize NeuroOne's investigational drug delivery neural device technology, which combines precision intracranial drug delivery with simultaneous neural recording. This integrated approach is designed to enable targeted therapy while providing real-time physiologic monitoring throughout treatment, offering investigators additional insight into both drug delivery and the effects on the surrounding neural environment.
David Wambeke, Chief Business Officer of NeuroOne, stated, "This collaboration with Mayo Clinic represents another important milestone in the continued expansion of our drug delivery platform. We believe our technology has the potential to become an enabling platform for targeted intracranial therapies by combining precision drug delivery with real-time neural recording."
The CCRF award represents an important milestone in advancing this therapeutic approach toward clinical evaluation. The collaboration further expands NeuroOne's growing portfolio of drug delivery initiatives and reflects increasing interest from leading academic investigators and biopharmaceutical companies in the Company's drug delivery platform.
NeuroOne markets a minimally invasive and high-definition electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System, and OneRF® Trigeminal Nerve Ablation System. For more information, visit nmtc1.com.
